What's New

News

2018/09/27
Updated information of CSR
2018/08/20
Nippon Kayaku launches Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK”, a humanized anti-human HER2 monoclonal Antibody
2018/03/23
Nippon Kayaku Receives Manufacture and Marketing Approval in Japan for Biosimilar of Trastuzumab Monoclonal Antibody
2017/09/28
Updated information of CSR
2017/08/31
Nippon Kayaku announces the final data analysis of a global phase 3 study of NK105, a novel macromolecular micelle encapsulating an anticancer drug, will be presented at the ESMO 2017 Congress
2017/04/26
Agreement on major articles of contract for collaboration for CT-P10, in Japan
2017/04/11
Submission of Application for Marketing Approval of CT-P6 Trastuzumab Biosimilar Monoclonal Antibody in Japan
2016/09/30
Updated information of CSR
2016/07/05
Results of Phase III study of NK105, a novel macromolecular micelle encapsulating an anticancer drug
2016/06/08
Announcement: Establishment of Joint Venture Company for MAB Production
2016/06/06
Notice Concerning Monthly Share Repurchase Results and Repurchase Completion
2016/06/05
The 100th anniversary of the Nippon Kayaku Group’s founding is on June 5, 2016.
2016/04/27
Nippon Kayaku Announces FDA Orphan Drug Designation to New Polymeric micelle Anti-Cancer Drug NK012 for Small Cell Lung Cancer
2016/03/30
We have published "Nippon Kayaku Commemorating 100 Years of Sukima Ideas".
2015/11/10
Nippon Kayaku Announces License Agreement with Eiger BioPharmaceuticals to Develop BestatinTM (ubenimex) for Inflammatory Diseases Involving LTB4
2015/10/06
Updated information of CSR
2015/10/05
Maintenance notification
2015/07/30
Nippon Kayaku Announces Start-up Clinical Trial in Japan as the part of Global Phase 3 Clinical Trial Program for CT-P6 in Breast Cancer
2015/06/08
Management Changes (Appointments & Transfers)
2015/04/21
We have published CSR Procurement.
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR